Stock Market & Financial Investment News

News Breaks November 28, 2012 08:45 EDT PRGO, CADX Perrigo confirms settlement of generic version of Ofirmev injection Perrigo (PRGO) confirmed that it has agreed to settle its Hatch-Waxman litigation relating to Ofirmev injection brought by Cadence (CADX). Under the terms of the settlement, Perrigo can launch a generic version of Ofirmev injection on December 6, 2020, or earlier under certain circumstances. In addition, Perrigo has secured the right to be the sole authorized generic distributor should Cadence elect to launch an authorized generic product. News For PRGO;CADX From The Last 14 Days Check below for free stories on PRGO;CADX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 23, 2013 08:15 EDT PRGO Perrigo to transfer common listing to NYSE from Nasdaq Subscribe for More Information May 13, 2013 10:58 EDT PRGO High option volume stocks: PRGO OMEX SCTY OPTR DNR Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.